李校堃 教授
硕士招生类型：
硕士招生专业：
博士招生类型：学术型
博士招生专业：基础医学方向
所在院系：医学院
联系方式：lixk1964@163.com
课题组链接：
研究方向
主要任职
科研业绩

微生物与生化药学（Microbial and Biochemical Pharmacy）
内分泌疾病组织化学（Histochemistry of endocrine diseases）

基因工程药物国家工程研究中心首席科学家
Principle Scientist of National Engineering Research Center of Genetic Medicine
生物反应器与药物开发教育部工程研究中心首席科学家
Principle Scientist of Bioreactor and Drug Development Reseach Center，Ministry of Education
浙江省生物技术制药工程重点实验室主任
Director of Zhejiang Provincial Key Laboratory of Biotechnology Pharmaceutical Engineering
中国发明协会常务理事
Managing Director of China Invention Association
中国生物工程学会常务理事
Managing Director of Chinese Society of Biotechnology
中国医药生物技术协会副理事长
Vice Chairman of China Medicinal Biotechnology Association
《Biotechnology Journal》编委
Editorial board of Biotechnology Journal
《浙江大学学报（医学版）》编委
Editorial board of Journal of Zhejiang University(Medical Sciences)

李校堃教授长期专注于重组蛋白药物基础理论研究与药物研发，聚焦于机体发育生长相关重要功能蛋白成纤维细胞生长因子家族（FGFs）：系统研究了FGFs促创伤主动愈合和功能修复理论；攻克FGFs成药技术瓶颈，在国际上率先研发3种原创自主知识产权FGFs基因工程一类新药（贝复济?、盖扶?、艾夫吉夫?）和1种三类载药医疗器械（创必复?）。应用于全国5500余家医院近6500****次，为各类创伤人群尤其是战创伤、重大灾害性创伤、糖尿病和老年疾病等慢性疾病引发的难愈性溃疡提供了重要治疗手段。在推动FGFs产业化的同时，深入研究FGFs在生命活动中的调控规律，首次提出“FGF代谢轴”理论，为FGFs拓展到代谢性疾病治疗领域奠定了理论基础。以第一或通讯作者在Nature, Cell Metab, Mol Cell, Circulation等发表论文196篇（IF≥10的8篇），他引5960次，H指数46，获Nature, The Lancet等专题评述。以第一完成人获2009年国家技术发明二等奖和2018年国家科技进步二等奖；获2017年何梁何利科学与技术进步奖、谈家桢生命科学奖和2018年光华工程科技奖等；核心技术获授权发明专利32项，转化及产业化7项，推动3家企业上市，累计销售额超50亿元。
Professor Li has long been focusing on the basic theoretical research and drug research and development of recombinant protein, especially focusing on important functional protein fibroblast growth factor family (FGFs) related to body growth and development. He has systematically studied the theory of FGFs in promoting wound healing and repairing function. Though overcoming the technical bottleneck of FGFs medicine formation, he took the lead in the development of original independent intellectual property FGFs genetic engineering medicine(Beifuji, Gaifu, and Aifujifu) and succeeded Third-Class drug carrying medical device (Chuangbifu). They have been applied to more than five thousand and five hundred hospitals nationwide for nearly sixty five million people, providing an important treatment method for the refractory ulcer caused by various trauma groups, especially war trauma, major disaster trauma, diabetes and elderly diseases. He has published one hundred and ninety six SCI papers, like Nature, Cell Metab, Mol Cell, Circulation etc. His work won special comments on Nature, the Lancet etc. As the first person, He won the second prize of national technology invention and National Science and technology progress award. He owns thirty two authorized invention patents among seven used for transformation and industrialization, making a total sales of more than RMB five billion.